Cargando…
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial
OBJECTIVES: We will investigate the effectiveness of high dose Interferon Beta 1a, compared to low dose Interferon Beta 1a (the base therapeutic regimen) in COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed) with moderate to severe disease TRIAL DESIGN: This is a single center, open label...
Autores principales: | Alavi Darazam, Ilad, Hatami, Firouze, Rabiei, Mohammad Mahdi, Pourhoseingholi, Mohamad Amin, Moradi, Omid, Shokouhi, Shervin, Hajesmaeili, Mohammad Reza, Shabani, Minoosh, Irvani, Seyed Sina Naghibi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586665/ https://www.ncbi.nlm.nih.gov/pubmed/33106183 http://dx.doi.org/10.1186/s13063-020-04812-2 |
Ejemplares similares
-
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021) -
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial
por: Irvani, Seyed Sina Naghibi, et al.
Publicado: (2020) -
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021) -
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021) -
One‐step and sequential SARSCOV‐2 polymerase chain reaction tests would not work every time
por: Hatami, Firouze, et al.
Publicado: (2022)